Literature DB >> 6104255

Effect of propranolol and prazosin on blood lipids. The Oslo Study.

P Leren, P O Foss, A Helgeland, I Hjermann, I Holme, P G Lund-Larsen.   

Abstract

In 23 hypertensive men, aged 47-55, propranolol reduced serum high-density-lipoprotein (HDL) cholesterol by 13% reduced the ratio of HDL to low-density-lipoprotein (LDL)+very-low-density-lipoprotein (VLDL) cholesterol by 15%, increased total triglycerides by 24%, and increased serum uric acid by 10%. Prazosin reduced total serum cholesterol by 9%, LDL+VLDL cholesterol by 10%, and total triglycerides by 16%. These changes are statistically highly significant. On combined treatment with propranolol and prazosin HDL cholesterol was still significantly reduced but changes in other blood lipids were small and insignificant. Uric acid remained elevated. When decisions about long-term therapy are made, such metabolic effects might be of special importance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6104255     DOI: 10.1016/s0140-6736(80)92888-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  59 in total

1.  Metabolic effects of carteolol and dilevalol in essential hypertension.

Authors:  T Baba; K Takebe; T Tomiyama
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.

Authors:  R Kirsten; K Nelson; G Weidinger; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  A randomized controlled trial of the effects of aerobic dance training on blood lipids among individuals with hypertension on a thiazide.

Authors:  Fatai A Maruf; Aderonke O Akinpelu; Babatunde L Salako
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-06-24

4.  Effects of prazosin and alphamethyldopa on blood lipids and lipoproteins in hypertensive patients.

Authors:  M Velasco; H Silva; E Feldstein; R Pellicer; J Morillo; A Urbina-Quintana; O Hernández-Pieretti
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Working ability and exercise tolerance during treatment of mild hypertension. II. A comparison between atenolol and prazosin medication.

Authors:  K Lange Andersen; W Ottmann; W Piatkowski; K A Green
Journal:  Int Arch Occup Environ Health       Date:  1985       Impact factor: 3.015

6.  Working ability and exercise tolerance during treatment of a mild hypertension. I. Comparison between a beta-adreno-receptor blocking drug and a calcium antagonist.

Authors:  K Lange Andersen; W Piatkowski; K A Green; W Ottmann
Journal:  Int Arch Occup Environ Health       Date:  1985       Impact factor: 3.015

7.  Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension.

Authors:  P van Brummelen; F R Bühler; F W Amann; P Bolli
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 8.  [Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-04-01

9.  Adrenergic mechanisms in control of plasma lipid concentrations.

Authors:  J L Day; J Metcalfe; C N Simpson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-17

Review 10.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.